tiprankstipranks
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
PremiumPress ReleasesCabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
1M ago
Cabaletta Bio Reveals Insights in Updated Corporate Presentation
PremiumCompany Announcements
Cabaletta Bio Reveals Insights in Updated Corporate Presentation
2M ago
Cabaletta Bio reports Q1 EPS (51c) , consensus (48c)
PremiumThe Fly
Cabaletta Bio reports Q1 EPS (51c) , consensus (48c)
2M ago
Cabaletta Bio price target raised to $33 from $31 at Morgan Stanley
PremiumThe FlyCabaletta Bio price target raised to $33 from $31 at Morgan Stanley
4M ago
Cabaletta Bio price target lowered to $34 from $35 at Wells Fargo
PremiumThe Fly
Cabaletta Bio price target lowered to $34 from $35 at Wells Fargo
4M ago
Cabaletta Bio price target raised to $30 from $25 at H.C. Wainwright
PremiumThe Fly
Cabaletta Bio price target raised to $30 from $25 at H.C. Wainwright
4M ago
Cabaletta Bio Receives Orphan Drug Status for CABA-201
PremiumCompany AnnouncementsCabaletta Bio Receives Orphan Drug Status for CABA-201
4M ago
Cabaletta Bio granted Orphan Drug designation to CABA-201
PremiumThe Fly
Cabaletta Bio granted Orphan Drug designation to CABA-201
4M ago
Cabaletta Bio treatment of systemic sclerosis granted orphan designation
PremiumThe Fly
Cabaletta Bio treatment of systemic sclerosis granted orphan designation
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100